There’s more to a long life than simply a long lifespan. The number of years we spend in good health, or healthspan, is key. With biotech spurring promising medical innovations, we look at how it can fit into investment portfolios.

Running up debts to buy foreign goods is unsustainable in the long term. Identifying the problem is simple, but we see no easy or quick escape for the U.S. from the imbalances built up over the last four decades.

Everyone has an opinion regarding the COVID-19 crisis; while they may all mean well, no one knows when this will end. They only thing that is true in every crisis I’ve been through (19 in 42 years), human nature does not change. You can measure fear.

The Coronavirus is changing how biotechs will be valued in the future. New technological innovations and a faster FDA approval process will contribute to future growth for these companies.

Market volatility is normal and to be expected. It is painful sometimes, but there are abundant opportunities if you are patient and stick to your strategy.

Market volatility is rampant. Coronavirus fears are equally so. Corrections in the market are inevitable. Here’s what we’re doing to prepare.